Back to Ovarian Cancer

NCT04294927

NCT04294927
Recruiting Not Applicable 🇦🇺 Australian site

Who may be able to join

Who might be able to join this trial:

  • You are a woman who has been confirmed to carry a specific harmful gene mutation in one of these genes: BRCA1, BRCA2, RAD51C, RAD51D, or BRIP1, tested at one of the participating medical centres
  • Your age falls within the range linked to your specific gene mutation: BRCA1 carriers aged 25–40, BRCA2 carriers aged 25–45, or RAD51C/RAD51D/BRIP1 carriers aged 25–50
  • You have finished having children and do not plan to have any more
  • You still have at least one fallopian tube (the tubes that connect the ovaries to the uterus)
  • You may be able to join even if you have had a previous cancer diagnosis, as long as it was not ovarian, fallopian tube, or peritoneal cancer
  • You are willing and able to give written consent to take part in the trial

Who may not be able to join:

  • You have already gone through menopause, either naturally or as a result of medical treatment
  • You are planning to have your ovaries removed within two years of joining the trial
  • You are not legally able to make your own decisions about medical care
  • You have already had both fallopian tubes removed
  • You have a personal history of ovarian cancer, fallopian tube cancer, or peritoneal cancer
  • You are currently being diagnosed with or treated for any active cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Medical Center Nijmegen
Registry
clinicaltrials_gov
Start date
1 March 2020
Est. completion
17 February 2040

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇩🇪 Germany 🇮🇪 Ireland 🇮🇹 Italy 🇲🇽 Mexico 🇳🇱 Netherlands 🇳🇴 Norway 🇵🇱 Poland 🇪🇸 Spain 🇸🇪 Sweden 🇺🇸 United States Uruguay

15 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

High grade serous (ovarian) cancer incidence

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov